Turnstone Biologics Quick Ratio (TSBX) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Turnstone Biologics Corp   (NASDAQ: TSBX)

Turnstone Biologics 's Quick Ratio

TSBX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2025, Quick Ratio deteriorated to 3.13 below Turnstone Biologics 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 92 other companies have achieved higher Quick Ratio than Turnstone Biologics in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 1191 to 1238.

Explain Quick Ratio?
How much Cash & cash equivalents TSBX´s has?
What are TSBX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TSBX Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -62.04 % -48.06 % -42.13 % 4.3 % -16.24 %
Y / Y Cash & cash equivalent Change -70.26 % -71.83 % -69.4 % -58.43 % 26.67 %
Quick Ratio MRQ 3.13 3.34 3.54 3.33 4
TSBX's Total Ranking # 1238 # 1191 # 1186 # 1124 # 1049
Seq. Current Liabilities Change -9.65 % -19.89 % -39.91 % -12.72 % 23.62 %
Seq. Cash & cash equivalent Change -15.34 % -24.38 % -36.03 % -27.38 % -19.82 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 93
Healthcare Sector # 444
Overall Market # 1214


Quick Ratio Statistics
High Average Low
9.23 5.04 2.64
(Dec 31 2022)   (Jun 30 2023)




Financial Statements
Turnstone Biologics 's Current Liabilities $ 6 Millions Visit TSBX's Balance sheet
Turnstone Biologics 's Cash & cash equivalent $ 19 Millions Visit TSBX's Balance sheet
Source of TSBX's Sales Visit TSBX's Sales by Geography


Cumulative Turnstone Biologics 's Quick Ratio

TSBX's Quick Ratio for the trailling 12 Months

TSBX Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -38.15 % -24.79 % -23.98 % 8.35 % 43.54 %
Y / Y Cash & cash equivalent TTM Growth -66.63 % -52.05 % -50.97 % -18.25 % 47.11 %
Quick Ratio TTM 3.35 3.61 4.29 5.01 6.21
Total Ranking TTM # 2872 # 3032 # 3167 # 3100 # 3013
Seq. Current Liabilities TTM Growth -22.02 % -12.13 % -10.64 % 1.01 % -5.18 %
Seq. Cash & cash equivalent TTM Growth -27.64 % -26.06 % -23.45 % -18.52 % 3.97 %

Quick ratio ranking by company, industry and sector >> Back to TSBX Financial Strength Comparisons >> Go to Compare TSBX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in TSBX's Current Liabilities to $5.93 millions, cumulative Quick Ratio to 3.35 below the TSBX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Turnstone Biologics . While Quick Ratio overall ranking has improved so far to 2872, from total ranking during the twelve months ending first quarter 2025 at 3032.

Explain Quick Ratio?
How much Cash & cash equivalents TSBX´s has?
What are TSBX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 139
Healthcare Sector # 810
Within the Market # 2872


trailing twelve months Quick Ratio Statistics
High Average Low
6.46 4.77 3.24
(Jun 30 2024)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Black Diamond Therapeutics Inc   8.50 $ 142.829  Millions$ 16.805  Millions
4d Molecular Therapeutics Inc   8.46 $ 293.225  Millions$ 34.677  Millions
Zura Bio Limited  8.26 $ 154.490  Millions$ 18.696  Millions
Krystal Biotech Inc   7.85 $ 681.986  Millions$ 86.896  Millions
Fate Therapeutics Inc   7.77 $ 222.830  Millions$ 28.673  Millions
Aligos Therapeutics Inc   7.35 $ 122.945  Millions$ 16.725  Millions
Compass Therapeutics Inc   7.28 $ 100.949  Millions$ 13.858  Millions
Revolution Medicines Inc   7.08 $ 2,137.171  Millions$ 301.842  Millions
Monte Rosa Therapeutics Inc   6.94 $ 290.594  Millions$ 41.852  Millions
Ginkgo Bioworks Holdings Inc   6.92 $ 473.691  Millions$ 68.433  Millions
Candel Therapeutics Inc   6.84 $ 100.687  Millions$ 14.715  Millions
Replimune Group Inc   6.77 $ 403.340  Millions$ 59.564  Millions
Lexeo Therapeutics Inc   6.64 $ 132.893  Millions$ 20.025  Millions
Repligen Corp  6.63 $ 708.855  Millions$ 106.969  Millions
Beam Therapeutics Inc   6.61 $ 1,150.337  Millions$ 174.131  Millions
Vir Biotechnology Inc   6.54 $ 686.967  Millions$ 105.004  Millions
Iteos Therapeutics Inc   6.54 $ 515.430  Millions$ 78.813  Millions
Scholar Rock Holding Corp  6.52 $ 295.013  Millions$ 45.223  Millions
Caribou Biosciences Inc   6.37 $ 183.948  Millions$ 28.887  Millions
Autolus Therapeutics Plc  6.27 $ 454.279  Millions$ 72.407  Millions
Metagenomi Therapeutics Inc   6.16 $ 204.993  Millions$ 33.265  Millions
Surrozen Inc   5.85 $ 90.390  Millions$ 15.448  Millions
Exozymes Inc   5.74 $ 6.986  Millions$ 1.217  Millions
Tenaya Therapeutics Inc   5.66 $ 71.667  Millions$ 12.654  Millions
Kyverna Therapeutics Inc   5.53 $ 220.150  Millions$ 39.789  Millions
Compugen Ltd  5.31 $ 93.877  Millions$ 17.691  Millions
Immunocore Holdings Plc  5.27 $ 882.811  Millions$ 167.641  Millions
Atyr Pharma Inc   5.17 $ 80.346  Millions$ 15.531  Millions
Inhibrx Biosciences Inc   5.07 $ 186.567  Millions$ 36.770  Millions
Vaxcyte Inc   4.82 $ 306.744  Millions$ 63.628  Millions

Date modified: 2026-08-29T17:48:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.